Munich — Bayer has acknowledged for the first time that lawsuits related to the controversial weed killer Roundup could force it to sell assets, issue new equity, or borrow money at unfavourable terms.

In its annual report published on Thursday, Bayer said that it “may incur considerable financial disadvantages” from pending suits as well as future cases from US plaintiffs who say the herbicide causes cancer...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now